Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
These Pt(IV) complexes showed comparable activity, of 2 orders of magnitude higher than reference drug oxaliplatin on three human (HCT 116, SW480, and HT-29) and one mouse (CT26) colon cancer cell lines.
|
30879295 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bmal1/BMAL1 regulation of rhythmic Mrp2/MRP2 expression was also confirmed in the colon cancer CT26 and Caco-2 cells.
|
31244920 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, intraperitoneal application of OXA/TA NPs-H restricted the growth of CT26 peritoneal colon cancer in vivo, improved the quality of life and prolonged the survival time of the model mice.
|
30553061 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vitro, the CT26 and MC38 murine colon cancer cell lines were shown to upregulate IDO expression following stimulation with interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α).
|
30824815 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, immunomodulatory strategies to boost the antitumor immune response induced by DaRT, and the response specificity, were investigated in the colon cancer CT26 mouse model.
|
31637474 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cell-Based IL-15:IL-15Rα Secreting Vaccine as an Effective Therapy for CT26 Colon Cancer in Mice.
|
31760731 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
To extend these in vitro findings, we have obtained mouse colon cancer MC38- and CT26-MEKi resistant syngeneic models (MC38-MR and CT26-MR).
|
31842958 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Different groups of CT26 mouse colon cancer cell line received various treatments of cisplatin, ACA, and AA nanocomplexes and then the samples were prepared for Z-scan studies.
|
31362112 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the in vivo experiment, colon cancer CT26-bearing mice were used to investigate the effects of RHPS in cytotoxicity and anticancer.
|
30471400 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used the CT26 colon cancer model to investigate the regulation of VISTA by hypoxia.
|
31088847 |
2019 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Together, these results suggest that QX exerts antitumor activity in CT26 mouse colon cancer model partially mediated by Foxo1-induced apoptosis and antitumor immune response.
|
31030593 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Colon cancer was established in 17 mice by injection of LS174T (N<sub>r</sub> = 9) or CT26 (N<sub>n</sub> = 8) cancer cells to simulate clinical responders and non-responders, respectively.
|
30225758 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
To address this, a CT-26 colon cancer xenograft model was established in mice since this cell line is insensitive to SHP099.
|
30972278 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
CT26 colon cancer cells were treated with 5-FU and oxaliplatin with or without HGF.
|
29374697 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current paper, three differently shaped Pluronic F-127-modified IONPs (nanocubes, nanoclusters, and nanorods) were compared side by side in three murine tumor models (4T1 breast cancer, B16 melanoma, and CT26 colon cancer).
|
30344459 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transiently transduced CT26 and HT29 colon cancer cells and stably expressing CT26/NIS-cODC cells were prepared.
|
30116045 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study, bone marrow‑derived dendritic cells from BALB/c mice and undifferentiated murine colon carcinoma CT26.WT cells were used as a cellular model to study the primary role of HMGB1 in colon cancer immunity.
|
29257231 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, CPT inhibited the growth, invasion, inflammation and angiogenesis in CT26 colon cancer, and at least partly, by regulating the PI3K/Akt/mTOR signaling and the nuclear translocation of HIF-1α.
|
30388517 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>In vivo</i> biodistribution and imaging studies were performed with positron emission tomography and magnetic resonance imaging (PET/MRI) studies to identify and quantitate <sup>89</sup>Zr-DS-5573a tumor uptake in a B7-H3-positive breast cancer model (MDA-MB-231) and a B7-H3-negative murine colon cancer model (CT26).
|
30128047 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated whether nalmefene, an opioid receptor inhibitor, could inhibit CT26 colon cancer cell growth through influencing cell glycolysis.
|
29267844 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed therapy with this system in a colon cancer xenograft model (CT26/Rluc).
|
29584688 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
PhenolaTi was found to be effective in vivo against colon (CT-26) and lung (LLC-1) murine cell lines in syngeneic hosts and toward a human colon cancer (HT-29) cell line in immune-deficient (Nude) mice, with an efficacy similar to that of known chemotherapy.
|
30203598 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
The photoresponsive DOX release and ROS generation by Ce6 mediated cytotoxic effect of DPRMs were demonstrated in vitro using CT-26 (mouse colon cancer) and HCT-116 (human colon cancer) cells.
|
29864270 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>Lycium barbarum</i> Polysaccharide Promotes Maturation of Dendritic Cell via Notch Signaling and Strengthens Dendritic Cell Mediated T Lymphocyte Cytotoxicity on Colon Cancer Cell CT26-WT.
|
29619065 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated whether three-dimensional (3D) dynamic contrast-enhanced ultrasound (DCE-US) imaging allows assessing early changes in tumor perfusion following antiangiogenic treatment (bevacizumab administered at a dose of 10 mg/kg b.w.), and whether these changes could predict treatment response in colon cancer tumors that either are responsive (LS174T tumors) or none responsive (CT26) to the proposed treatment.
|
28721500 |
2017 |